{"name":"Telavant, Inc.","slug":"telavant-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PF-06480605","genericName":"PF-06480605","slug":"pf-06480605","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"PF-06480605","genericName":"PF-06480605","slug":"pf-06480605","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNRG9uNDdDd2xyQ0sxRU9RdEowUGN4VzR4RUNIRU52MEotbzdCT3lIU3doLUhiMHVWTlFabXlEelYwMFlhYUdXd0ZTQ1JDRGo4VjdxamZxaGpiVHBpbEdwc3RBSm1NejcxSHpwZ2tjYUJTdG9OY3pSTnEwcDV6VWdBRU94ZVpWMzZMU3h3cXFodWhJMmlVLTZSUUtMb1N2WlkxYW1PdU56b0p0UkxCTTdBQkdrbEhmQQ?oc=5","date":"2024-01-12","type":"deal","source":"Fierce Biotech","summary":"JPM24: Roivant’s Matt Gline has ‘pangs of regret’ for letting Telavant go, but he's ready to deal again - Fierce Biotech","headline":"JPM24: Roivant’s Matt Gline has ‘pangs of regret’ for letting Telavant go, but he's ready to deal again","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNQzQwQU5yYXRSaERNaWs3N1l4MHM1Um1Xd0NiczR3T0tGVjQ0M19jYXBtQS1yQl9SQ2QzMjRLdlVIUGJPTUxDSG9kYm1ZLTFLN2NRZTNTUDJqNHc1ZXVROWhpbmZyeWJ6cXlEQW9VTVNmbVcwc0h5Wmw3djV6dGF6VU5EMTFKbjdHcUE?oc=5","date":"2023-10-31","type":"deal","source":"Pharma Voice","summary":"Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says - Pharma Voice","headline":"Roivant’s $7B Roche deal was a ‘moment of opportunity,’ CEO says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOUVY5cDJGVEdQXzZlM2R3NjNIX2o5ZXRDWGFlbVBJaHhLdHh6b1ZPS0h0UjQwdnZQeU01OWtnT1hDTnlGczhrOHE2YVN6b0tHRENCVFBsNGU5SWJqcTBrQ1lhVTFqbnhzUmtpSjdGZzhyd01FU1VZVGV6T2VtX2RhZlAtUzI3OU1yRm00dThjNTFXc1dmWFEzQXJxRGFJRU5oTHhJNmxHdmVLMHPSAbABQVVfeXFMUEJNQzNPdWxONENMWVJjVG5rS2VzNUJaOEQ1dmJJSkFrQ3BybllDMmpMMi1lbVJ2TDhqdDRJWWx1b2Z0bWZsVTRUUmdEb01tMHJJVFlnVkxSUlNfYzlLbEtPT3lJQlRoMjMzZ0JGVjh4dlV2MEd5MWxQd3FMZkxEZzg4MTlvazQ0eklkZXRBRzVqd28xUFEwTm55M2lReHdhT2xHTUFkdzFFTnhLQ0hCZFk?oc=5","date":"2023-10-24","type":"deal","source":"medicaldialogues.in","summary":"Roche acquires Telavant Holdings for USD 7.1 billion - medicaldialogues.in","headline":"Roche acquires Telavant Holdings for USD 7.1 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPWjFTa2t2akxUbzN5Tms1WXZneGg4S09KTElsNDVFYTl0TDhlZ2xBdmRUY0F4TlpwVGZidXlIX0F5VF8wWkUtTHlGeWxrcW5MZVJPekYyU0tjbHE3bmY4SV9XUkVtYU1HeGEyTlZhaVZfcFB6dFdsT0JBd25PZ3ZxdmlpNENmUjVtSGkzd0MwX1ZaTjhMOFRzT2ZwRdIBoAFBVV95cUxPbmQ0cGQ1bWVBT3N5eklqS2x5MDFqbEN4NDNpekdkX0drRV9zRWtWdEgwdFN1MjBVdENteExxYWRyd3dxWHliblVkQUk3TUItek5qTGk1anRJdGs0V3FaTUV2N2ZFcUZveTloSmc2OEg0ZjN1a19MQWgxOGdjSnYyZmtLaEdaUnBpYXRrdTFBUGhqVDVuc0dCM3NjMll4ZjVM?oc=5","date":"2023-10-23","type":"deal","source":"CNBC","summary":"Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings - CNBC","headline":"Swiss pharma giant Roche agrees $7.1 billion deal to buy Telavant Holdings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPLW4tVjhWN3pjUmh3TEdtdHhfRHZLR2pzT3loMXh0Wk8yam5QTDRDZlRQMG45dFNMeHc0ZnV4SUEzeWRreTVGRmZCY1o3TWREdmlBSzJyV21DelpaQ1R4akIwQ0xRQ2h2aDAzcmJkaTM2YV9qamFJU01lWEVKNlN3d1hjZzVBc01aX3hvU0JFRG9YM0lPSzN2aGZhMzE4SWl2Rmlpb0tjTzg4Q3N6VHNZb1Q0aG4?oc=5","date":"2023-10-23","type":"pipeline","source":"Bloomberg.com","summary":"Roche to Pay $7.1 Billion for Telavant to Boost Its Pipeline - Bloomberg.com","headline":"Roche to Pay $7.1 Billion for Telavant to Boost Its Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxOcDdCRjI3T0dtOVlaS1NqVFV2NE9PUWlXTmJDREZ3LTRVRVpmRFUtbzBuVlZvTVo4MlR3dGZQdzR1a0M2WEsxM1FwYmxnZjBSYXFjbDNyUVlsd3JmeGFSbnJndmc2cmFoZ2M3LVZHbVJ4Y2gtSEQ5TVFhN2w4Z0hoUFhnWGpvUmFXZzVKaEVWVFhpOWRKVVhXbl92RE1uMnFSS1FKOE9QUk1hWkFqcThmcUljdXU?oc=5","date":"2023-10-23","type":"deal","source":"WSJ","summary":"Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion - WSJ","headline":"Roche to Buy Bowel-Disease Drug From Roivant, Pfizer for More Than $7 Billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPVTZramJleWJfN2hqLTVrVDFMYW1nVHBiTEJScC1rdVBBYkhJNm9aNmxYM0cxR2I3T05kanNJUXoxNF96dG1wODlEMURCY3RlUzJhbFVQLUpOQ3VkanJoU29hS2NJQm9tcHNqY2lURnQ2Ul9WcmtKSWhvenk0TVVuekxZV1M3NzFCWGhFUFVYS240WV9jSFZZNVN3?oc=5","date":"2023-10-23","type":"deal","source":"BioPharma Dive","summary":"Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary - BioPharma Dive","headline":"Roche to gain gut disease drug in $7.1B deal for Roivant subsidiary","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNN1hCWUQyYjY4NUFSaktRaU1TU3BSUTNLV0hNaF9JaGx2enZJalZYVkltaFBISnVSdV84UTFhYUQwR0s4TnB0bEpWbDNqYThUX250N0ctNmRmSWhVSERxX3pmbGZiZFBDMXRMN1JvdWhPaDJNV00xS3JoeUtrTW9pOVpfOGtLN1dJVXI2WXlncmdZRms?oc=5","date":"2023-10-23","type":"deal","source":"reuters.com","summary":"Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal - reuters.com","headline":"Roche buys U.S. rights to Roivant bowel disease drug in $7.1 billion deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPVnEzdWFTYUhmMXd2b2QtaThJTFI5U1NHMkJJZDFfY1RpalFSUHdXNURuMktRUGp0TGt0c1NRajJ3T1A5dTg3NFlxSjdzLV91V1BaUzBDM1E4MGVUT29Ka0k4Z282NHY4TGtBbTZ6ejlfRDRZdjRFR3FWWDlGVW83MzJUUWhETE1ISVdDU3JVMA?oc=5","date":"2023-10-23","type":"deal","source":"Barron's","summary":"Roche to Buy Telavant From Roivant Sciences, Pfizer for $7.1 Billion. One Stock Looks a Winner. - Barron's","headline":"Roche to Buy Telavant From Roivant Sciences, Pfizer for $7.1 Billion. One Stock Looks a Winner. - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE5aTWZGZ001SmNNcGRJZ0l5RlZncG1Ya2ZZX19WTXZsZVljNVVlQ015a05VWUhxVTg0Wk80RUU1QzJneGRRVm1scTVYd1B6YWJ4WXE5bXVtVy16MkxrZWRoalBHWGZjOWpQTEhETzBJQTRCWDYtTlg2eGJWWQ?oc=5","date":"2023-10-23","type":"deal","source":"pharmaphorum","summary":"Rumour confirmed as Roche buys Telavant for $7.1bn - pharmaphorum","headline":"Rumour confirmed as Roche buys Telavant for $7.1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPT1FiUHJkTGZyU3lGQjQ3NVZ0NnF6MlZZQlRKUmZpNW1zZEJaSXBqMUhLUko2bHFiVUUxaTFNSHVNZlQ5YllKUGxMbkphRlR0ckJCZElocS1jUGtzd19xQV9KcmRZQ0tKMmwyeVRXQm5hMURpTG9VdnlySm5RTVRsLTk4RU5fU09lazdGWm5xODVqVldIdmpWbDBvcXJNUlc1NmJ6NXFCdGxoUWc?oc=5","date":"2023-10-23","type":"deal","source":"Pharmaceutical Technology","summary":"Signal: Roche to buy ulcerative colitis drug from Roivant for $7.1bn - Pharmaceutical Technology","headline":"Signal: Roche to buy ulcerative colitis drug from Roivant for $7.1bn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNcmpLZ1FDV0Zrall3eHo4Z3E5TmlhZjYxY2hjZTVOUnpNbmFFT2lYa29fZzVWa0hnZzY0cmhTd2Rub2NaenZMTDNOY1ZSZ05LQXZUbzRtWHNsUDJ4eFlmODhXeEQ0X2tiQWpPU19TNDZiUFpzWDk3RFFUaGJYWExWQWo2N0ZJUkFVbXNuaWNfaEt6eGk3SGhGZDhFS0hWeHBZNU5waWZxZHBCZw?oc=5","date":"2023-10-23","type":"pipeline","source":"European Pharmaceutical Review","summary":"Roche to gain rights to novel antibody for IBD - European Pharmaceutical Review","headline":"Roche to gain rights to novel antibody for IBD","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}